incretin receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-11-20 and is reviewed periodically as new material appears.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Peptide-based pharmaceutical products such as tirzepatide require controlled temperature management to preserve structural integrity. Manufacturer labeling generally specifies refrigeration at 2 to 8 degrees Celsius before first use, with protection from light and freezing. Exposure to repeated temperature cycling can promote aggregation or deamidation, which alters the analytical profile even when the visible solution appears unchanged. Once a product is in use, the permitted storage window and temperature range are defined by the specific labeled presentation rather than by general peptide rules.
Identity and purity assessment of tirzepatide relies primarily on reversed-phase high-performance liquid chromatography coupled with ultraviolet detection. Mass spectrometry, often in electrospray ionization mode, confirms the molecular mass and detects sequence-related impurities. Peptide mapping after enzymatic digestion provides residue-level confirmation of the backbone. Each method addresses a different question: chromatography for purity and related substances, mass measurement for identity, and mapping for sequence fidelity. No single technique covers all three.
Research and analytical settings increasingly require documentation of peptide origin and chain of custody. Certificate of analysis documents typically report purity by chromatographic area, mass confirmation, appearance, and residual solvent or counterion content. Independent verification by an accredited laboratory is common when a material will be used in a regulated study. Open questions remain about how well compendial methods transfer between laboratories, and about which impurity thresholds are meaningful for materials not intended for clinical use.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | 39-residue backbone with non-natural residues |
| Receptor targets | GIP and GLP-1 | Dual incretin receptor agonist |
| Approximate molecular mass | 4,813 Da | Calculated from the peptide sequence |
| Administration route | Subcutaneous injection | Weekly schedule in approved products |
| Albumin binding | Present | Mediated by a C20 fatty diacid side chain |
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
Purified material is typically handled as a lyophilized powder kept at or below minus twenty degrees Celsius, shielded from light and moisture. In that state the solid remains stable for extended periods, although repeated freeze-thaw cycling can encourage aggregation. Once dissolved, aqueous solutions are less durable and are generally held cold and used within a brief window. Buffer composition, pH and ionic strength all influence degradation rates, and mildly acidic to neutral conditions are commonly examined. Actual shelf life depends on formulation, concentration and container, so stability limits are established experimentally rather than assumed.
Verification of research-grade material involves checking purity, sequence and counter-ion content against a certificate of analysis. Reported purity figures usually reflect chromatographic area percentage and do not by themselves establish biological activity. Independent laboratories may repeat mass confirmation and peptide mapping to detect substitutions or truncations. Open questions concern how residual solvents, trace metals and subtle conformational variants affect measured behavior, and how consistently different suppliers define their specifications. Documentation of analytical methods matters as much as the headline purity number when results are compared across studies.
== Chemistry == Buspirone was originally classified as an azaspirodecanedione, shortened to azapirone or azaspirone due to the fact that its chemical structure contained this moiety, and other drugs with similar structures were labeled as such as well. However, despite all being called azapirones, not all of them actually contain the azapirodecanedione component, and most in fact do not or contain a variation of it. Additionally, many azapirones are also pyrimidinylpiperazines, though again this does not apply to them all. Drugs classed as azapirones can be identified by their -spirone or -pirone suffix.
== External links == Clinical trial number NCT02793128 for "The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study (Olympus)" at ClinicalTrials.gov Clinical trial number NCT05243550 for "A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (ENVISION)" at ClinicalTrials.gov
The WHO AWaRe (Access, Watch, Reserve) guidance and antibiotic book has been introduced to guide antibiotic choice for the 30 most common infections in adults and children to reduce inappropriate prescribing in primary care and hospitals. Narrow-spectrum antibiotics are preferred due to their lower resistance potential, and broad-spectrum antibiotics are only recommended for people with more severe symptoms. Some antibiotics are more likely to confer resistance, so are kept as reserve antibiotics in the AWaRe book. Various diagnostic strategies have been employed to prevent the overuse of antifungal therapy in the clinic, proving a safe alternative to empirical antifungal therapy, and thus underpinning antifungal stewardship schemes.
Sources: en.wikipedia.org
== Church service == Prior to his call to full-time service, Kearon's service in the church included being president of the Bristol England Stake and area seventy. At the time of his call as a general authority, Kearon was living in Clevedon, which is a town in North Somerset, England. In 2011, he was appointed as an assistant executive director of the church's priesthood and media services departments. From August 2012 to August 2015, he served as a counselor in the presidency of the church's Europe Area, before becoming the area's president in August 2015. In May 2017, it was announced that Kearon would become a member of the Presidency of the Seventy on August 1, with responsibility for the church's North America Northwest and North America West areas. Kearon has been vocal on the topic of religious freedom, stating that "religious freedom means nothing if you protect your own religious practice while neglecting the practice of others, especially those who might be less secure and able to defend themselves. It only works if you protect the rights of everyone." In 2016, he addressed European Commission officials at a European Union summit asking for assistance during the refugee crisis. Kearon was quoted in a New York Times op-ed with regards to his work with refugees saying, “Their story is our story, not that many years ago.” While serving as president of the church's Europe Area, Kearon initiated programs to assist refugees in the area and also led out in the church working to support existing programs to help refugees..
Cordelia goes to Alastair to gently break the news of Charles’ new engagement to him. Alastair already knew and is not happy when Cordelia tells him she eavesdropped on his recent conversation with Charles.
Antimicrobial peptides Auriclosene (NVC-422) - see also Keratoconjunctivitis Bacteriocin Chlorine dioxide Copper alloys CLR01 (Molecular tweezers) found to inhibit Ebola, Zika or possibly SARS-CoV-2 Cyanovirin-N General so called "Drug repurposing" for example in case of SARS-CoV-2/COVID-19 Griffithsin Interferon Nanomedicines "Novel Anti-Infectives" research by Helmholtz Centre for Infection Research Peracetic acid Scytovirin Urumin
Sources: en.wikipedia.org
== History == Paniz-Mondolfi was born in Caracas, Venezuela in 1976. His mother is a pediatrician and his father an architect. His grandfather, Edgardo Mondolfi Otero, a biologist and zoologist. Two of his uncles were physicians with special ambitions in the field of sciences and research. His childhood was shared between Caracas and Kenya. Paniz-Mondolfi has a master's degree in parasitology and tropical diseases; he did international fellowships in microbiology, molecular genetics, and skin disease. He also did a second medical residency in the United States in pathology. He isolated and described a new species of parasite that had infected a NY resident, and a new mycobacterium that sickened two people in Connecticut. He earned an MD and PhD and studied under Jacinto Convit the leprosy researcher. He was a pathologist at the IDB Biomedical Research Institute in Barquisimeto, Venezuela until 2019 when he fled to the United States. He is the founder of the Venezuelan Science Incubator, an independent health research organization. Paniz-Mondolfi is assistant professor of pathology, molecular and cell-based medicine at the Mount Sinai Icahn School of Medicine. He is also affiliated with the Yale Cancer Center. In 2020 he focused his research on the COVID-19 pandemic and the effects the virus had on minority children. His research findings have been published in several medical journals including: the European Society of Clinical Microbiology and Infectious Diseases, The American Association for the Advancement of Science, and The Lancet.
Other notable derivatives then result from further modification of this template, with saturation of the 7,8-double bond of etorphine resulting in the even more potent dihydroetorphine (up to 12,000× potency of morphine) and acetylation of the 3-hydroxy group of etorphine resulting in acetorphine (8700× morphine). While the isopentyl homologue of etorphine, known as M-140, is nearly three times more potent, its 7,8-dihydro and 3-acetyl derivatives are less potent than the corresponding derivatives of etorphine at 11,000 and 1300 times morphine, respectively. Replacing the N-methyl group with cyclopropylmethyl results in opioid antagonists such as diprenorphine (M5050, which is used as an antidote to reverse the effects of etorphine, M99), and partial agonists such as buprenorphine, which is widely used in the treatment of opioid addiction, although conversely the N-cyclopropylmethyl derivative of M-140, which has the code number M-320, retains similarly potent μ-opioid full agonist activity to the N-methyl derivative. More complex substitutions on the ring system can be used to produce selective δ-opioid agonists such as BU-48, and selective κ-opioid agonists such as CL 110,393.
== Organization == Americold has more than 245 locations worldwide. It is a publicly traded REIT focused on temperature-controlled warehouses. Americold owns and operates a quarry in Carthage Underground both for the excavated stone and uses the caverns and refrigerated storage chambers.
== Hazards == Care should be taken when using a cold trap not to condense oxygen gas into the cold trap, visible as light blue liquid. Liquid oxygen is potentially explosive, and this is especially true if the trap has been used to trap solvent. Oxygen can be condensed into a cold trap if a pump has sucked air through the trap when the trap is very cold, e.g. when cooled with liquid nitrogen. Besides oxygen, many hazardous gases emitted in reactions, e.g. sulfur dioxide, chloromethane, condense into cold traps.
Sources: en.wikipedia.org
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.
A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.
The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.
The peptide backbone and its fatty acid side chain are susceptible to degradation at elevated temperatures. Refrigeration slows hydrolysis, oxidation, and aggregation processes. Labeled storage ranges reflect stability data generated under defined conditions.